SAGE THERAPEUTICS, INC. (NASDAQ:SAGE) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
Sage Therapeutics,Inc. (the Company) held its Annual Meeting of
Stockholders (the Annual Meeting) on June7, 2017. As of April10,
2017, the record date for the Annual Meeting, there were
37,328,237 outstanding shares of the Companys common stock. The
Companys stockholders voted on the following matters, which are
described in detail in the Companys Definitive Proxy Statement
filed with the U.S. Securities and Exchange Commission (SEC) on
April28, 2017: (i)to elect Michael Cola and Jeffrey M. Jonas as
ClassIII directors of the Company to each serve for a three-year
term expiring at the Companys annual meeting of stockholders in
2020 and until their successors have been duly elected and
qualified (Proposal 1), (ii) to ratify the appointment of
PricewaterhouseCoopers LLP as the Companys independent registered
public accounting firm for the fiscal year ending December31,
2017 (Proposal 2) and (iii)to hold an advisory vote to approve
the compensation paid to the Companys named executive officers
(Proposal 3).
The Companys stockholders approved the ClassIII director nominees
recommended for election in Proposal 1 at the Annual Meeting. The
Companys stockholders voted for ClassIII directors as follows:
|
ClassIII Director Nominee |
For | Against | Abstain | BrokerNon-Votes | ||||||||||||
|
Michael Cola |
22,173,881 | 7,670,296 | 144,978 | 3,342,203 | ||||||||||||
|
Jeffrey M. Jonas |
25,862,154 | 3,982,023 | 144,978 | 3,342,203 |
The Companys stockholders approved Proposal 2. The votes cast at
the Annual Meeting were as follows:
| For | Against | Abstain | ||
| 33,269,910 | 37,494 | 23,954 |
The Companys stockholders voted to approve, on an advisory basis,
the compensation of the named executive officers in Proposal 3.
The votes cast at the Annual Meeting were as follows:
| For | Against | Abstain | BrokerNon-Votes | |||
| 29,870,567 | 92,634 | 25,954 | 3,342,203 |
No other matters were submitted to or voted on by the Companys
stockholders at the Annual Meeting.
* * *
About SAGE THERAPEUTICS, INC. (NASDAQ:SAGE)
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. Its product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors. Its SAGE-718 is a product candidate selected for development from its NMDA receptor program.
